ω-Aminopentyl-phosphorigsaeurediethylester | 53253-55-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: ω-Aminopentyl-phosphorigsaeurediethylester
• 英文别名: ω-Aminopentyl-phosphonic acid diethyl ester；(5-amino-pentyl)-phosphonic acid diethyl ester；diethyl 5-aminopentylphosphonate；5-diethoxyphosphorylpentan-1-amine
• CAS: 53253-55-7
• 化学式: C₉H₂₂NO₃P
• 分子量: 223.252
• InChiKey: FXUUJOXFIGPRSB-UHFFFAOYSA-N

物化性质

• 沸点：
  311.8±25.0 °C(Predicted)
• 密度：
  1.025±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ω-Aminopentyl-phosphorigsaeurediethylester 在 盐酸 、 水 、 氢溴酸 作用下， 以 乙醇 为溶剂， 反应 7.0h， 生成 {5-[((4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)amino]pentyl}phosphonic acid
  参考文献：
  名称：

  Acyclic phosph(on)ate inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase

  摘要：

  The pathogenic protozoa responsible for malaria lack enzymes for the de novo synthesis of purines and rely on purine salvage from the host. In Plasmodium falciparum (Pf), hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT) converts hypoxanthine to inosine monophosphate and is essential for purine salvage making the enzyme an anti-malarial drug target. We have synthesized a number of simple acyclic aza-C-nucleosides and shown that some are potent inhibitors of Pf HGXPRT while showing excellent selectivity for the Pf versus the human enzyme. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.02.016
• 作为产物：
  描述：

  二乙基(5-溴戊基)膦酸酯 在 一水合肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 ω-Aminopentyl-phosphorigsaeurediethylester
  参考文献：
  名称：

  d-Glucose-based azacrown ethers with a phosphonoalkyl side chain: application as enantioselective phase transfer catalysts

  摘要：

  Five chiral alpha-D-glucose-based monoaza-15-crown-5 ethers with a phosphonoalkyl side chain 5a-e have been synthesized. The substituent at the nitrogen atom has a major influence on the cation extraction ability of the azacrown. The new lariat ethers 5a-e show significant asymmetric induction as phase transfer catalysts in the Michael addition of 2-nitropropane to chalcone. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(99)00224-4

文献信息

• [EN] PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PHOSPHORIBOSYLTRANSFÉRASES ET LEURS UTILISATIONS
  申请人：IND RES LTD

  公开号：WO2012150866A1

  公开（公告）日：2012-11-08

  The invention relates to compounds of formula (I) that are inhibitors of hypoxanthine and/or guanine purine phosphoribosyltransferases and to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit hypoxanthine and/or guanine purine phosphoribosyltransferases. Such diseases include malaria.

  这项发明涉及到式（I）的化合物，这些化合物是次黄嘌呤和/或鸟嘌呤磷酸核糖转移酶的抑制剂，以及含有这些化合物的药物组合物、制备这些化合物的方法，以及治疗希望抑制次黄嘌呤和/或鸟嘌呤磷酸核糖转移酶的疾病或症状的方法。这些疾病包括疟疾。
• [EN] NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS<br/>[FR] NOUVELLES AMIDINES DE THIOPHENE, COMPOSITIONS DE CES AMIDINES ET PROCEDE POUR TRAITER DES MALADIES ET DES ETATS MEDIES PAR LE COMPLEMENT
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2003099805A1

  公开（公告）日：2003-12-04

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本规范中定义的芳香族或杂环芳基。
• Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20040009995A1

  公开（公告）日：2004-01-15

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 and R 7 are defined in the specification, Z is SO or SO 2 , and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用公式I的化合物的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中在规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本文中定义的芳香族或杂环芳基。
• Process for the manufacture of aminoalkyl-phosponic acid esters
  申请人：Ciba-Geigy Corporation

  公开号：US04151229A1

  公开（公告）日：1979-04-24

  The invention relates to a process for the manufacture of aminoalkyl-phosphonic acid esters by catalytic hydrogenation of cyanoalkylphosphonic acid esters. After having separated the catalyst and solvents, in general the crude product is distilled. The esters which can be obtained by the process of this invention are of importance as intermediate products, because all reactions of amines can be carried out with these products. They can also be used as additives for amine curing agents for epoxide resins in order to achieve flame-retarding properties.

  这项发明涉及一种通过催化加氢氰基磷酸酯制备氨基磷酸酯的方法。通常在分离催化剂和溶剂后，粗产品会被蒸馏。本发明的方法可以获得的酯是重要的中间体产品，因为所有胺的反应都可以用这些产品进行。它们还可以用作环氧树脂的胺固化剂的添加剂，以实现阻燃性能。
• DENTAL MATERIALS ON THE BASIS OF UREA GROUP-CONTAINING MONOMERS
  申请人：IVOCLAR VIVADENT AG

  公开号：US20160151249A1

  公开（公告）日：2016-06-02

  Dental material which contains a urea derivative according to general formula I, in which R 1 and R 2 are in each case independently of each other an aliphatic C 1 -C 15 radical which can be interrupted by —O—, —S—, —CO—O—; X is a radically polymerizable group; Y is a radically polymerizable group or an acid group; n, m are in each case independently of each other 1, 2, or 3.

  含有一种按照一般式I的脲衍生物的牙科材料，其中R1和R2分别为独立的脂肪族C1-C15基团，可以被—O—，—S—，—CO—O—打断；X是一个基团，可以被自由基聚合；Y是一个自由基聚合基团或酸基团；n，m分别独立地为1、2或3。